TriangleDifluoromethylornithine (NCT04696029)
Difluoromethylornithine trial for Medulloblastoma (NCT04696029). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients diagnosed by age 21 with molecularly high-risk, very-high-risk, or relapsed or refractory medulloblastoma. After prior treatment, they must have no detectable disease or stable, small-volume residual disease.
The idea: eflornithine, also called DFMO, blocks an enzyme needed to make polyamines that support cell growth. Patients take it by mouth twice daily for two years. Researchers compare progression-free survival with historical controls. Molecular testing determines the risk group; timing and prior-radiation rules also apply.
This phase 2 study plans 118 patients. Michael Huang chairs it; 25 US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.